2-(5-amino-2-methoxyphenoxy)ethan-1-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(5-amino-2-methoxyphenoxy)ethan-1-ol
• 英文别名: 2-(5-amino-2-methoxyphenoxy)ethanol
• 化学式: C₉H₁₃NO₃
• mdl: MFCD11147840
• 分子量: 183.207
• InChiKey: UDMFSWVKMKAPIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  64.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(5-amino-2-methoxyphenoxy)ethan-1-ol 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 20.0h， 生成 2-((6-cyano-7-methyl-3H-imidazo[4,5-c]pyridin-2-yl)thio)-N-(3-(2-hydroxyethoxy)-4-methoxyphenyl)acetamide
  参考文献：
  名称：

  Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics

  摘要：

  取代的-3H-咪唑[4,5-c]吡啶和1H-吡咯[2,3-c]吡啶系列新型胞外核苷酸焦磷酸酶/磷酸二酯酶-1 (ENPP1)及相关化合物，其作为ENPP1的抑制剂是有用的；制造这些化合物的方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与ENPP1功能障碍相关的疾病的方法。

  公开号：

  US20200039979A1
• 作为产物：
  描述：

  2-甲氧基-5-硝基苯酚 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 19.0h， 生成 2-(5-amino-2-methoxyphenoxy)ethan-1-ol
  参考文献：
  名称：

  Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics

  摘要：

  取代的-3H-咪唑[4,5-c]吡啶和1H-吡咯[2,3-c]吡啶系列新型胞外核苷酸焦磷酸酶/磷酸二酯酶-1 (ENPP1)及相关化合物，其作为ENPP1的抑制剂是有用的；制造这些化合物的方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与ENPP1功能障碍相关的疾病的方法。

  公开号：

  US20200039979A1

文献信息

• [EN] COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY<br/>[FR] COMPOSES PRESENTANT UNE AFFINITE AVEC LE RECEPTEUR 5HT2C ET UTILISATION THERAPEUTIQUE DE CEUX-CI
  申请人：GLAXO GROUP LTD

  公开号：WO2003089409A1

  公开（公告）日：2003-10-30

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: wherein R1 is hydrogen, hydroxy, fluoro, chloro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy or haloC1-6alkoxy; m is 0 when ======= is a double bond and m is 1 when ======= is a single bond; R2 is hydrogen, halogen, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is -(CH2-CH2)-, -(CH=CH)-, -(CH2)3-, -C(CH3)2-, -(CH=CH-CH2)-, -(CH2-CH=CH)- or a group -(CHR5)- wherein R5 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1-6alkylthio; R3 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1-6alkylthio, hydroxy, amino, mono- or di-C1-6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, arylC1-6alkyl, arylC1-6alkyloxy, arylC1-6alkylthio or COOR6, CONR7R8 or COR9 wherein R6, R7, R8 and R9 are independently hydrogen or C1-6alkyl; p is 0, 1 or 2 or 3; R4 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, -CH2- or NR10 wherein R10 is hydrogen or C1-6alkyl; D is a single bond, -CH2-, -(CH2)2- or -CH=CH-; and Z is an optionally substituted C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, an optionally substituted N-linked 4 to 7 membered heterocyclic group, or Z is -NR11R12 where R11 and R12 are independently hydrogen or C1-6alkyl. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression and anxiety, are also disclosed.

  公式（I）的化合物或其药学上可接受的盐被披露：其中R1是氢，羟基，氟，氯，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基或卤代C1-6烷氧基；当=======是双键时，m为0，当=======是单键时，m为1；R2是氢，卤素，氰基，硝基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C1-6烷硫基，氨基，单或双C1-6烷基氨基或N-连接的4至7成员杂环基；X是-(CH2-CH2)-，-(CH=CH)-，-(CH2)3-，-C(CH3)2-，-(CH=CH-CH2)-，-(CH2-CH=CH)-或一个基团-(CHR5)-其中R5是氢，卤素，羟基，氰基，硝基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基或C1-6烷硫基；R3是卤素，氰基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基，C1-6烷硫基，羟基，氨基，单或双C1-6烷基氨基，N-连接的4至7成员杂环基，硝基，卤代C1-6烷基，卤代C1-6烷氧基，芳基，芳基C1-6烷基，芳基C1-6烷氧基，芳基C1-6烷硫基或COOR6，CONR7R8或COR9其中R6，R7，R8和R9独立地是氢或C1-6烷基；p是0，1，2或3；R4是氢，卤素，羟基，氰基，硝基，C1-6烷基，C1-6烷酰基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C1-6烷硫基，氨基，单或双C1-6烷基氨基或N-连接的4至7成员杂环基；Y是氧，硫，-CH2-或NR10其中R10是氢或C1-6烷基；D是单键，-CH2-，-(CH2)2-或-CH=CH-；Z是含有至少一个氮的可选择取代的C-连接的4至7成员杂环基，可选择取代的N-连接的4至7成员杂环基，或Z是-NR11R12其中R11和R12独立地是氢或C1-6烷基。还披露了其制备方法和在治疗中的用途，特别是用于中枢神经系统疾病如抑郁症和焦虑症。
• NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
  申请人：Stein Philip D.

  公开号：US20090011994A1

  公开（公告）日：2009-01-08

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了根据公式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式， 其中 R 1 ，R 2 ，R 3 ，R 8 和R 9 在此定义。 此外，本申请提供了含有至少一种根据公式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症，通过给予根据公式I的化��物的治疗有效剂量。
• Compounds having affinity at 5ht2C receptor and use thereof in therapy
  申请人：Damiani Federica

  公开号：US20050203079A1

  公开（公告）日：2005-09-15

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: wherein R 1 is hydrogen, hydroxy, fluoro, chloro, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, C 1-6 alkoxy or haloC 1-6 alkoxy; m is 0 when is a double bond and m is 1 when is a single bond; R 2 is hydrogen, halogen, cyano, nitro, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkylthio, amino, mono- or di-C 1-6 alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is —(CH 2 —CH 2 )—, —(CH═CH)—, —(CH 2 ) 3 —, —C(CH 3 ) 2 —, —(CH═CH—CH 2 )—, —(CH 2 —CH═CH)— or a group —(CHR 5 )— wherein R 5 is hydrogen, halogen, hydroxy, cyano, nitro, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy or C 1-6 alkylthio; R 3 is halogen, cyano, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, C 1-6 alkoxy, C 1-6 alkylthio, hydroxy, amino, mono- or di-C 1-6 alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC 1-6 alkyl, haloC 1-6 alkoxy, aryl, arylC 1-6 alkyl, arylC 1-6 alkyloxy, arylC 1-6 alkylthio or COOR 6 , CONR 7 R 8 or COR 9 wherein R 6 , R 7 , R 8 and R 9 are independently hydrogen or C 1-6 alkyl; p is 0, 1 or 2 or 3; R 4 is hydrogen, halogen, hydroxy, cyano, nitro, C 1-6 alkyl, C 1-6 alkanoyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkylthio, amino, mono- or di-C 1-6 alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, —CH 2 — or NR 10 wherein R 10 is hydrogen or C 1-6 alkyl; D is a single bond, —CH 2 —, —(CH 2 ) 2 — or —CH═CH—; and Z is an optionally substituted C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, an optionally substituted N-linked 4 to 7 membered heterocyclic group, or Z is —NR 11 R 12 where R 11 and R 12 are independently hydrogen or C 1-6 alkyl. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression and anxiety, are also disclosed.

  公开了化学式（I）或其药学上可接受的盐的化合物：其中R1是氢，羟基，氟，氯，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基或卤代C1-6烷氧基; 当是双键时，m为0，当是单键时，m为1; R2是氢，卤素，氰基，硝基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C1-6硫基，氨基，单基或二基C1-6烷基氨基或N-连接的4至7成员杂环基; X是—（CH2—CH2）—，—（CH═CH）—，—（CH2）3—，—C（CH3）2—，—（CH═CH—CH2）—，—（CH2—CH═CH）—或一个—（CHR5）—基团，其中R5是氢，卤素，羟基，氰基，硝基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基或C1-6硫基; R3是卤素，氰基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基，C1-6硫基，羟基，氨基，单基或二基C1-6烷基氨基，N-连接的4至7成员杂环基，硝基，卤代C1-6烷基，卤代C1-6烷氧基，芳基，芳基C1-6烷基，芳基C1-6烷氧基，芳基C1-6硫基或COOR6，CONR7R8或COR9，其中R6，R7，R8和R9独立地为氢或C1-6烷基; p为0、1、2或3; R4是氢，卤素，羟基，氰基，硝基，C1-6烷基，C1-6酰基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C1-6硫基，氨基，单基或二基C1-6烷基氨基或N-连接的4至7成员杂环基; Y是氧，硫，—CH2—或NR10，其中R10是氢或C1-6烷基; D是单键，—CH2—，—（CH2）2—或—CH═CH—; Z是一个可选择取代的含有至少一个氮的C-连接的4至7成员杂环基，一个可选择取代的N-连接的4至7成员杂环基，或Z是—NR11R12，其中R11和R12独立地为氢或C1-6烷基。还公开了制备方法及其在治疗中的用途，特别是在中枢神经系统疾病如抑郁症和焦虑症中的应用。
• SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
  申请人：Stein Philip D.

  公开号：US20110144060A1

  公开（公告）日：2011-06-16

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了一种化合物，包括所有立体异构体、溶剂化合物、前药和其制备的药学上可接受的形式，其化学式为I式，其中R1、R2、R3、R8和R9的定义如本文所述。此外，本申请还提供了含有至少一种I式化合物和可选的至少一种其他治疗剂的药物组合物。最后，本申请提供了通过给予I式化合物的治疗有效剂量来治疗患有MCHR-1调节性疾病或疾病的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症。
• Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst
  申请人：L'OREAL

  公开号：US10251827B2

  公开（公告）日：2019-04-09

  The invention relates to a process for dyeing keratin fibers, comprising the use of one or more metal catalysts and of a composition (A) comprising: —one or more oxidizing agents, and —at least one monoaminobenzene of formula (I), or an addition salt or solvate thereof in which the radicals R1 to R5 represent, independently of each other: a hydrogen atom; a halogen atom, a C1-C6 alkyl radical, a C1-C6 alkoxy radical, a carboxylic radical (—COOH), a sulfonic radical (—S03 H); two of the adjacent radicals R1 to R5 possibly forming, with the carbon atoms that bear them, a saturated or unsaturated 5- to 7-membered ring, optionally comprising from 1 to 2 heteroatoms, preferably oxygen, the said ring being optionally fused with a saturated or unsaturated 5- to 6-membered ring; on condition that at least one of the radicals R1 to R5 represents an optionally substituted alkoxy radical and preferably at least one of the other radicals R1 to R5 is a hydrogen atom.

  本发明涉及一种角蛋白纤维染色工艺，包括使用一种或多种金属催化剂和一种组合物（A），组合物（A）包括： -一种或多种氧化剂，和 -至少一种式（I）的单胺苯，或其加成盐或溶液，其中自由基 R1 至 R5 各自代表：氢原子、卤素原子、C1-C6 烷基、C1-C6 烷氧基、羧基 (-COOH)、磺酸基 (-S03 H)；R1 至 R5 中相邻的两个基团可与含有它们的碳原子形成饱和或不饱和的 5 至 7 元环，可选择包含 1 至 2 个杂原子，最好是氧，所述环可选择与饱和或不饱和的 5 至 6 元环融合；条件是 R1 至 R5 自由基中至少有一个代表任选取代的烷氧基，且 R1 至 R5 自由基中至少有一个是氢原子。